<DOC>
	<DOCNO>NCT01584674</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy KLOX Biophotonic System patient moderate severe facial acne vulgaris use split-face design ( treated hemiface v untreated hemiface ) .</brief_summary>
	<brief_title>A Clinical Trial Evaluating Safety Efficacy KLOX Biophotonic System Moderate Severe Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Male Female 16 30 year age . 2 . Fitzpatrick skin type I IV . 3 . Known medical history active acne vulgaris least 6 month . 4 . Moderatetosevere facial acne , define : Moderate define patient IGA 3 20 40 inflammatory lesion ( papule pustule ) 1 nodule . Severe define patient IGA 4 great 40 inflammatory lesion presence 2 nodule and/or inflammatory scar type lesion . Also note patient similar disease stage side face . 5 . The patient must clinical examination prior treatment . 6 . The patient must sign consent form . 7 . The patient must willing return followup visit . 8 . Females child bear potential must negative pregnancy test result baseline male female patient must willing adhere birth control method . 1 . Active skin infection face . Patient must active , localized systemic infection . 2 . Facial aesthetic procedure , include laser therapy injectables within last 6 month . 3 . Enrollment another acne study dermatological study use light therapy include tan bed within 120 day enrollment . Patients must take part intend take part another study liable interfere study whatever region body consider 30 day prior study start 30 day follow completion study . 4 . History head and/or neck irradiation . 5 . Use hormonal contraception prohibit unless birth control stable past 3 month . Note patient presently take take past 30 day Cyproterone Acetate + Ethinyl Estradiol ( Diane35 ) eligible study . 6 . Any facial dermatological condition could hinder interfere clinical assessment . 7 . Immunosuppression and/or cortisone therapy past 4 month . 8 . Bleeding diathesis . 9 . Medications supplement affect coagulation . 10 . Isotretinoin within last 24 week . 11 . Pregnant , breastfeed pregnancy plan trial . 12 . History facial nerve palsy mark facial asymmetry . 13 . History neuromuscular disorder . 14 . Prior facial surgery alters subcutaneous tissue ( e.g. , rhytidectomy ) . 15 . Use nonacne topical medication could interfere study treatment . 16 . Physical psychiatric condition investigator deems would preclude participation study . ( e.g . Polycystic Ovary disease ) 17 . Unwillingness refrain excess sun exposure tan bed heal process</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>